Niagen Bioscience, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $129.4 | $99.6 | $83.6 | $72.0 | $67.4 |
| Operating income | $16.3 | $7.7 | -$5.6 | -$18.6 | -$27.1 |
| Net income | $17.4 | $8.6 | -$4.9 | -$16.5 | -$27.1 |
| Cash Flow Statement | |||||
| Share repurchases | $0.3 | $0.0 | — | — | — |
Shares outstanding 79.6M · Free float 23.6%
Annual filing data through FY ended December 31, 2025; float as of August 26, 2026.